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BACKGROUND: Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-
threatening event for schizophrenic subjects treated with clozapine.
METHODS: To examine the genetic factor for CIAG, a genome-wide pharmacogenomic analysis was conducted
using 50 subjects with CIAG and 2905 control subjects.
RESULTS: We identiﬁed a signiﬁcant association in the human leukocyte antigen (HLA) region (rs1800625, p 5 3.46
3 1029, odds ratio [OR] 5 3.8); therefore, subsequent HLA typing was performed. We detected a signiﬁcant
association of HLA-B*59:01 with CIAG (p 5 3.81 3 1028, OR 5 10.7) and conﬁrmed this association by comparing
with an independent clozapine-tolerant control group (n 5 380, p 5 2.97 3 1025, OR 5 6.3). As we observed that the
OR of CIA (OR: 9.315.8) was approximately double that in CIG (OR: 4.47.4), we hypothesized that the CIG
subjects were a mixed population of those who potentially would develop CIA and those who would not develop CIA
(non-CIA). This hypothesis allowed the proportion of the CIG who were non-CIA to be calculated, enabling us to
estimate the positive predictive value of the nonrisk allele on non-CIA in CIG subjects. Assuming this model, we
estimated that 1) 50% of CIG subjects would be non-CIA; and 2) 60% of the CIG subjects without the risk allele
would be non-CIA and therefore not expected to develop CIA.
CONCLUSIONS: Our results suggest that HLA-B*59:01 is a risk factor for CIAG in the Japanese population.
Furthermore, if our model is true, the results suggest that rechallenging certain CIG subjects with clozapine may not
be always contraindicated.
Keywords: Genome-wide association study, Human leukocyte antigen, Pharmacogenomics, Schizophrenia, Side
effect, Single nucleotide polymorphism636
Biohttp://dx.doi.org/10.1016/j.biopsych.2015.12.006Schizophrenia is a chronic, serious, and disabling mental
disorder with a lifetime prevalence of approximately 1% of
the world population (1). Antipsychotics are the most useful
therapeutic option for schizophrenia; however, approximately
one third of patients do not respond adequately to ﬁrst-line
antipsychotics, resulting in treatment-resistant schizo-
phrenia (TRS) (2,3).
Clozapine (CLZ) is a gold standard drug for managing TRS,
with a lower incidence of movement abnormality and efﬁcacy
superior to that of other antipsychotics in the management of
TRS (2-5). Despite its efﬁcacy with TRS, the use of CLZ
is signiﬁcantly restricted by severe side effects such as& 2016 Society of Biological Psychiatry. This is an open access a
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc
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SEE COMMENTARYCLZ-induced agranulocytosis (CIA)/CLZ-induced granulocyto-
penia (CIG) (CIAG), which is rare but potentially life threatening.
CIAG events are observed in approximately 1% (for CIA)
and 3% (for CIG) of CLZ-treatment patients, although the
prevalence of CIA differs between populations (Caucasian:
.3% .9%; Asian: greater than 1%; Japanese: 1.1%) (6-11).
In the clinical setting, patients treated with CLZ require
frequent blood monitoring for reduced neutrophil count, an
indication of CIG and CIA. One of the main reasons for this is
that, in general, CIG and CIA are considered to be a continuous
phenotype; psychiatrists expect to control the development of
CIA by detecting patients at the less serious CIG stage (12).rticle under the
-nd/4.0/).
al ISSN: 0006-3223
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PsychiatryHowever, as psychiatrists recognize based on experience, and
as Hummer et al. (13) reported, some patients with CIG may
not go on to experience a serious outcome such as immediate
development of CIA (i.e., benign or transient neutropenia)
(12,13). For example, a routine blood examination showing an
absolute neutrophil count (ANC) of 1400 cells/mm3 may result
in discontinuation of CLZ (as this is below the Japanese cutoff
level of 1500 cells/mm3 at which discontinuing CLZ treatment
is mandatory), but the ANC may then recover quickly to an
acceptable value. This may be because an ANC of around
1500 cells/mm3 can ﬂuctuate; for example, it may increase with
exercise (14,15) or decrease with viral infection (16).
In such clinical situations, a perfect genetic test to screen
for the risk of CIAG before treatment by CLZ is not always
mandatory. As described, frequent blood monitoring can be
used to detect CIA before CIG develops. Also, CLZ is one of
the last treatment options for TRS; the psychiatrist may have
little choice other than CLZ treatment. In this regard, a
screening test may be useful for reducing the frequency of
blood monitoring, thus relieving the burden on quality of life
and reducing cost. More importantly, however, psychiatrists
need more information on whether or not rechallenging is
possible or need a screening test to select CIAG patients who
can be treated again with CLZ as a rechallenge.
To date, several pharmacogenetic/pharmacogenomic (PGx)
studies have been carried out, mainly in Caucasian populations;
however, there is no report to clarify the difference between CIA
and CIG. For example, classical candidate gene-based pharma-
cogenetic studies suggested that a speciﬁc sequence variant in
human leukocyte antigen (HLA) (HLA-DQB1, 6672G . C) was
associated with CIA, but the signiﬁcance was modest (p  .001)
(17,18). A recent PGx study using a genome-wide association
approach and Exome sequencing analysis reported a large
impact on CIAG genetics: it showed that CIAG was associated
with two independent amino acid changes in HLA-B (158T:
p = 6.4 3 10210) and HLA-DQB1 (126Q: p = 4.7 3 10214) (19).
It is of note that the p values surpassed the genome-wide
signiﬁcance threshold (5 3 1028), although these associations
were detected by imputation of nonsynonymous single nucleo-
tide polymorphisms (SNPs) of HLA genes and not by the
genotyping of classical HLA alleles.
In this study, we aimed to explore the genetic risk for CIAG in
the Japanese population by a genome-wide SNP survey.
Although the sample size of CIAG subjects was small, we
detected signiﬁcant SNPs in the HLA region compared with
healthy control subjects drawn from the general population. To
detect the responsible risk allele, we conducted classical HLA
typing for the CIAG subjects and for CLZ-tolerant control subjects,
which showed that a speciﬁc allele in HLA-B was signiﬁcantly
associated with CIAG. We investigated the clinical utility of this risk
allele and whether it could increase posterior probability in the
screening test for CIAG or could provide information regarding the
possibility of CLZ rechallenging for CIG subjects.
METHODS AND MATERIALS
Ethical Statement
After providing a complete description of the study to the
subjects, written informed consent was obtained. The ethicsBiological Psyccommittees of each university, institute, and hospital partic-
ipating in this project approved this study.
Participants
CIAG Subjects. Fifty-two patients with CIAG were included
(28 male and 24 female patients, age 44.0 6 15.6 years old).
Of these, 23 were diagnosed with CIA, deﬁned as a decrease
in ANC to less than 500 cells/mm3, and 29 were diagnosed
with CIG, deﬁned as an ANC between 500 cells/mm3 and 1500
cells/mm3 or for three of these subjects as leukopenia (white
blood cell count less than 3000 cells/mm3). These criteria were
followed by the Clozaril Patient Monitoring Service in Japan
and many other countries, which can reﬂect a real-world
clinical setting. All subjects experienced CIAG within 180 days
of ﬁrst being prescribed CLZ, in accordance with the deﬁnition
of CIAG in a previous paper (20). All of the subjects were
diagnosed as TRS, and all identiﬁed themselves as Japanese.
Healthy Comparison Subjects. A total of 2948 subjects
(1120 male and 1828 female subjects; age 37.0 6 15.2 years
old) were genotyped as healthy control subjects; they had no
personal history of mental disorders and were Japanese
descent by self-report. Among them, 1108 subjects were
nurses at Fujita Health University Hospital (21), while the
others were recruited from the general population.
CLZ-Tolerant Control Subjects. For the classical HLA
association analysis, we recruited 380 CLZ-tolerant individuals
(210 male and 170 female individuals, age 42.7 6 11.8 years
old) who had been treated with CLZ for more than 180 days
without suffering from CIAG. Again, all of the subjects were
diagnosed as having TRS and self-reported as Japanese.
Genotyping and Quality Control
In the PGx analysis, we genotyped the CIAG cases and the
healthy comparison subjects using the Illumina HumanOm-
niExpressExome v1.0 (for 825 healthy comparison subjects) or
v1.2 (for the rest of the subjects) (Illumina, San Diego,
California).
The following quality control (QC) procedure was applied: 1)
we extracted overlapping SNPs between the v1.0 and v1.2
chips; 2) we ensured gender consistency by investigating the
SNPs on chromosome X (one CIAG subject); 3) we removed
the subjects with a low call rate , .99 (null subjects); and 4) we
removed subjects with two degrees or less of relatedness
using an identity-by-state analysis (22 healthy comparison
subjects). After this ﬁrst QC ﬁltering, 51 CIAG and 2926
healthy comparison subjects were still eligible, with 643,234
SNPs with a minor allele frequency of more than 1%. To
investigate the population structures as following QC, we
carried out principal component analysis (22). Using HapMap
datasets for four populations (Japanese in Tokyo; Han Chi-
nese in Beijing; Yoruba in Ibadan, Nigeria; and Utah residents
with ancestry from northern and western Europe), we con-
ﬁrmed that samples in the East Asian population were grouped
in one cluster (Supplemental Figure S1). Then, using only the
East Asian HapMap populations (Japanese in Tokyo and Han
Chinese in Beijing), we classiﬁed the population clusters,hiatry October 15, 2016; 80:636–642 www.sobp.org/journal 637
Figure 1. Manhattan plot for the genome-wide pharmacogenomic
results. Red line indicates genome-wide signiﬁcance (5 3 1028). The
y axis is 2log10(p values) of the single nucleotide polymorphisms and the
x axis is chromosomal position (hg19).
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clusters (Supplemental Figure S1) (23). We conﬁrmed that the
11 CIAG subjects recruited from Ryukyu Hospital were
classiﬁed in the Japanese-Ryukyu clusters. The subjects in
these two Japanese clusters were selected by visual inspec-
tion, with 22 subjects (one CIAG and 21 healthy comparison
subjects) being excluded as outliers. To calculate more
precise eigenvectors for association analysis, we carried out
further principal component analysis for the selected CIAG
and healthy comparison subjects. The SNPs with a call rate
,.99 and with large deviations from the Hardy Weinberg
equilibrium (p value of the exact test ,1 3 1025) in the
control group were also removed. Finally, we ﬁltered SNPs by
minor allele frequency of more than 1% in control subjects,
leaving 522,694 SNPs, 50 CIAG subjects (22 CIA and 28 CIG),
and 2905 healthy comparison subjects.
In the HLA analysis, genotyping of the HLA alleles of HLA-
A, HLA-C, HLA-B, and HLA-DRB1 genes was performed using
WAKFlow HLA typing kit (Wakunaga, Hiroshima, Japan) and a
Luminex Multi-Analyte Proﬁling system (xMAP; Luminex,
Austin, Texas).
Statistical Analysis in the PGx
The association of the direct genotyped SNPs was assessed
by a logistic regression analysis with adjustment of sex and
the ﬁrst two eigenvectors as covariates using PLINK ver1.9
(https://www.cog-genomics.org/plink2/) (24). Regional plots
were generated using LocusZoom (25). The association of
HLA alleles (dominant model) between CIAG and healthy
comparison/CLZ-tolerant control subjects was evaluated
using a 2 3 2 Fisher’s exact test in R (www.r-project.org).
The statistical level of signiﬁcance was set at p , 5 3 1028 for
the genome-wide SNP analysis and the HLA analysis.
Clinical Performance of HLA-B*59:01 as a Genetic
Test
To assess the clinical utility of the detected risk in HLA-B
(HLA-B*59:01), we calculated sensitivity and speciﬁcity, a
standard statistical measure of the performance of the test.
We also estimated positive predictive value (PPV) and negative
predictive value (NPV) assuming 1%, 3%, and 4% prevalence
for CIA, CIG, and CIAG, respectively, as prior probabilities.
Based on the PGx results, described later in Results, we
hypothesized that CIG subjects were a mixed population of
those with the potential to go on to develop CIA (CIAestimated)
and those whose neutrophil count had simply decreased
below the recommended cutoff line and who would not
develop CIA (non-CIAestimated) (12,13). We therefore focused
on the CIG subjects to estimate the proportion who were non-
CIAestimated.
Assume that ϕ is the proportion of the CIG who are
non-CIAestimated (i.e., ϕ = non-CIAestimated/CIG) and that
P(CIGobserved), P(CIAobserved), and P(Controlobserved) are the
proportions of patients observed to have the risk allele in the
CIG, CIA, and control (i.e., healthy comparison subjects and
CLZ-tolerant control subjects) groups, respectively. In line with
this assumption, we hypothesized that the proportion between
the probability of CIAestimated with the risk allele in the CIG
subjects and that without the risk allele in the CIG subjects638 Biological Psychiatry October 15, 2016; 80:636–642 www.sobp.ocorresponds with the proportion between the CIA subjects
observed to have the risk allele and those without the risk
allele. This would also be the case with the non-CIAestimated
subjects, which is compatible with the healthy comparison
subjects and CLZ-tolerant control subjects (Supplemental
Figure S2). To calculate ϕ, we used the following formulas:
P CIGobservedð Þ 5 f3P non-CIAestimatedð Þ1ð12fÞ
3P CIAestimatedð Þ f3P Controlobservedð Þ1ð12fÞ
3P CIAobservedð Þ
After solving for ϕ, we could estimate the number of subjects
with the risk allele (under the dominant model) for non-
CIAestimated [5number of CIGobserved 3 ϕ 3 P(non-
CIAobserved)] and CIAestimated [5number of CIGobserved 3
(12ϕ) 3 P(CIAobserved)] in the CIG group. Then, we examined
the statistical measure of the performance of the test to
assess the utility of the nonrisk allele on the non-CIAestimated,
who are the safest subjects for rechallenging: sensitivity,
speciﬁcity, PPV, and NPV. It is of note that sensitivity and
speciﬁcity are assumed in the theoretical model (we could not
divide subjects into non-CIA and CIA in the CIG group in the
real world), but PPV (the proportion of non-CIA in the CIG
without the risk allele) is the most informative value because
we can speculate the validity of CLZ rechallenging to the CIG.
RESULTS
Genome-wide PGx Analysis
A quantile-quantile plot was generated using the logistic
regression test (Supplemental Figure S3) and the genomic
inﬂation factor (λGC) based on median chi-square statistics
was 1, which indicates that population stratiﬁcation was
controlled by the eigenvectors.
Figure 1 shows a Manhattan plot of the data. The top SNPs
of the association are listed in Table 1. SNPs in the major
histocompatibility complex (MHC) were redundant due to
linkage disequilibrium, so we listed only SNPs with genome-
wide signiﬁcance. For regions other than the MHC, SNPs with
p , 1 3 1025 were listed; all of the top SNPs with p , 1 3
1025 are listed in Supplemental Table S1.
The SNPs in the MHC region showed genome-wide
signiﬁcance (i.e., p , 5 3 1028), and the top hit in this region
was rs1800625 located around 32 megabase in chromosomerg/journal
Table 1. Results for the Association Between CIAG and Control Subjects
CHR SNP BP A1 A2 F_A F_U OR (95% CIs) p Closest Gene
6 rs1800625 32152442 G A .30 .084 3.78 (2.43–5.87) 3.46E-09 PBX2 (MHC)
6 rs2269418 32180120 G T .30 .094 3.60 (2.29–5.66) 2.69E-08 NOTCH4 (MHC)
6 rs3213468 32183158 A G .30 .094 3.58 (2.28–5.62) 2.89E-08 NOTCH4 (MHC)
6 rs2071282 32188943 T C .30 .095 3.56 (2.27–5.60) 3.45E-08 NOTCH4 (MHC)
3 rs3749448 7188116 A G .37 .20 2.96 (1.90–4.61) 1.60E-06 GRM7
12 rs646782 50482211 G A .14 .051 3.94 (2.15–7.23) 9.59E-06 SMARCD1
Due to tight LD in MHC, only SNPs with p less than 5E-8 for MHC region were listed. For other region, SNPs with p less than 1E-5 were listed.
A1, nonreference allele; A2, reference allele; BP, base position based on hg19; CHR, chromosome; CI, conﬁdence interval; CIAG, clozapine-
induced agranulocytosis/granulocytopenia; F_A, frequency of A1 in cases; F_U, frequency of A1 in healthy comparison subjects; LD, linkage
disequilibrium; MHC, major histocompatibility complex; OR, odds ratio for A1; SNP, single nucleotide polymorphism.
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Figure S4). The other regions of top association were seen at
rs3749448 in the glutamate receptor, metabotropic 7 (GRM7,
p 5 1.6 3 1026, OR 5 3.0; Supplemental Figure S5), and
rs646782 in SWI/SNF related, matrix associated, action
dependent regulator of chromatin, subfamily D, member 1
(SMARCD1) (p 5 9.1 3 1026, OR 5 3.9; Supplemental
Figure S5).
To detect the responsible HLA allele, a classical HLA typing
(HLA-A, HLA-C, HLA-B, and HLA-DRB1) was conducted to
assess the association of HLA alleles between CIAG (n 5 50)
and a subset of healthy comparison subjects (n 5 1891) of
which most were from the general population (n 5 1739) and
the rest were nurses (n 5 152). We detected that a speciﬁc
allele of HLA-B*59:01 showed signiﬁcant association with
CIAG in the Japanese population (dominant model: p 5 3.8
3 1028, OR 5 10.7; Table 2; all of the association results are
listed in Supplemental Table S2). Interestingly, the narrow
phenotype subjects with CIA (n 5 22) showed a greater effect
size (OR 5 15.8), indicating that the core phenotype might
extract a purer risk for CIAG despite the lower statistical power
due to the small sample size (p 5 2.8 3 1026; Table 2). We
also found a trend for signiﬁcant association of HLA-
DRB1*04:05 (p 5 5.2 3 1025, OR 5 3.4; Supplemental
Table S2); however, this allele is in linkage disequilibrium with
HLA-B*59:01 (D′  .95 and r2  .1). The conditional analysis
with adjustment of HLA-B*59:01 revealed only a nominal
signiﬁcant association between HLA-DRB1*04:05 and CIAG
(p 5 .034), and so this association was correlated with that of
HLA-B*59:01.Table 2. Association of HLA-B*59:01 With CIAG
Allele Count f
Comparison 2 Allele 1 1 Alle
CIAG (n 5 50) vs. Healthy Comparison Subjects (n 5 1891) 12
CIA (n 5 22) vs. Healthy Comparison Subjects (n 5 1891) 7
CIG (n 5 28) vs. Healthy Comparison Subjects (n 5 1891) 5
CIAG (n 5 50) vs. Tolerant Control Subjects (n 5 380) 12
CIA (n 5 22) vs. Tolerant Control Subjects (n 5 380) 7
CIG (n 5 28) vs. Tolerant Control Subjects (n 5 380) 5
CI, conﬁdence interval; CIA, clozapine-induced agranulocytosis; CIAG,
induced granulocytopenia; OR, odds ratio.
a2 allele, samples with 2 alleles of HLA-B*59:01; 1 allele, samples with 1
Biological PsycTo validate the signiﬁcant association of HLA-B*59:01
between the CIAG and healthy comparison subjects and to ﬁnd
novel risk alleles, we genotyped a total of 380 CLZ-tolerant
control subjects as an independent comparison dataset (HLA-A,
HLA-C, HLA-B, and HLA-DRB1). Again, a signiﬁcant association
was detected between the CIAG group and the CLZ-tolerant
control subjects in HLA-B*59:01 (p 5 3.0 3 1025, OR 5 6.3;
Table 2; all of the association results are listed in Supplemental
Table S3). The narrow phenotype, CIA, again showed a greater
effect size (OR 5 9.3) than that for CIG (OR 5 4.4).
To assess the clinical utility for the risk allele of HLA-
B*59:01, standard statistical measures of test performance
were calculated (Table 3). We obtained low sensitivity and PPV
but high speciﬁcity and NPV; however, the acceptable line for
clinical use was not reached.Simulated Performance of HLA-B*59:01 for CLZ
Rechallenging
The PGx results showed a large difference in effect size
between CIA and CIG (CIA . CIG). We therefore assumed a
simple model where CIG consists of a mixture of subjects on the
way to developing CIA (CIAestimated) and subjects whose ANC
had simply decreased to less than 1500 cell/mm3 by chance or
due to an unknown risk factor and who would not develop CIA
(non-CIAestimated) (12,13). Using this model, we examined as an
explorative analysis its clinical utility, i.e., whether this informa-
tion can be a reasonable predictor for identifying among CIG
subjects those that are non-CIAestimated and those that are
CIAestimated. The values for ϕ (non-CIAestimated/CIG) wereor Casea Allele Count for Controla
le 0 Allele 2 Allele 1 1 Allele 0 Allele p OR 95% CIs
38 54 1837 3.81E-08 10.7 4.8–22.4
15 2.78E-06 15.8 5.2–43.2
23 1.32E-03 7.4 2.1–20.9
38 18 362 2.97E-05 6.3 2.6–15.1
15 1.39E-04 9.3 2.8–28.1
23 .015 4.4 1.2–13.7
clozapine-induced agranulocytosis/granulocytopenia; CIG, clozapine-
allele of HLA-B*59:01; 0 allele, samples with null allele of HLA-B*59:01.
hiatry October 15, 2016; 80:636–642 www.sobp.org/journal 639
Table 3. Diagnostic Performance of HLA-B*59:01 on CIAG
Comparison Sensitivity Speciﬁcity PPVa NPVa PARa PARPa (%)
CIAG (n 5 50) vs. Healthy Comparison Subjects (n 5 1891) .240 .971 .259 .968 .00843 21.1
CIA (n 5 22) vs. Healthy Comparison Subjects (n 5 1891) .318 .971 .101 .993 .00296 29.6
CIG (n 5 28) vs. Healthy Comparison Subjects (n 5 1891) .179 .971 .162 .975 .00451 15.0
CIAG (n 5 50) vs. Tolerant Control Subjects (n 5 380) .240 .953 .174 .968 .00783 19.6
CIA (n 5 22) vs. Tolerant Control Subjects (n 5 380) .318 .953 .064 .993 .00282 28.2
CIG (n 5 28) vs. Tolerant Control Subjects (n 5 380) .179 .953 .104 .974 .00402 13.4
CIA, clozapine-induced agranulocytosis; CIAG, clozapine-induced agranulocytosis/granulocytopenia; CIG, clozapine-induced granulocytopenia;
NPV, negative predictive value; PAR, population attributable risk; PARP, population attributable risk percent; PPV, positive predictive value.
aAssuming 1%, 3%, and 4% prevalence for CIA, CIG, and CIAG, respectively.
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comparison subjects and 51.6% for the CLZ-tolerant control
subjects), indicating that half of the subjects in the CIG group
had minimal risk of developing CIA. The estimated allelic
distributions of HLA-B*59:01 are listed in Table 4, calculated
based on P(CIAobserved) and P(non-CIAobserved). In this 2 3 2
table, it is of note that 1) 82% of the CIG subjects did not have
the risk allele; and 2) the PPV for detecting non-CIAestimated
subjects in the CIG group without the risk allele was moderate
(60%).DISCUSSION
Through the genome-wide SNP and classical HLA analyses,
we identiﬁed a risk allele for CIAG at HLA-B in people of
Japanese ancestry. It is of note that HLA-B was reported as a
risk factor for CIAG in Caucasian subjects in a recent PGx
study (19); our results therefore support this association.
However, SNP 158T in HLA-B, the risk allele detected by
Goldstein et al. (19), is not compatible with HLA-B*59:01
detected in this study.
HLA-B*59:01, which has not been reported as a risk for side
effects induced by CLZ or other drugs, is not common in the
Japanese population (the allele frequency is 1.5% in our
control subjects and 2.0% in the Japanese population based
on the HLA laboratory dataset URL: http://www.hla.or.jp/
haplo/haplonavi.php?type=haplo&lang=en). Interestingly,
based on the publicly available database (http://www.allelefre
quencies.net/), the allele is virtually nonexistent in other
populations such as Caucasian and African, the exception
being East Asian populations (e.g., in the Chinese and Korean
populations the allele frequency is .1  2%). This worldwide
allelic distribution might be the cause of the differentTable 4. Diagnostic Performance of Nonrisk Allele (Alleles Exce
Calculated Based on Samples non-CIAestimated
a (%)
CIA vs. Healthy Comparison Subjects Risk allele (2) 46.8
(ϕ 5 48.2%) Risk allele (1) 1.4
Total 48.2
CIA vs. Tolerant Control Subjects Risk allele (2) 49.1
(ϕ 5 51.6%) Risk allele (1) 2.4
Total 51.6
CIA, clozapine-induced agranulocytosis; CIG, clozapine-induced g
predictive value.
aProportion of the non-CIAestimated and CIAestimated samples were calcul
bAssuming 48.2% and 51.6% incidence based on healthy comparison
640 Biological Psychiatry October 15, 2016; 80:636–642 www.sobp.oprevalences of CIAG (for example, the East Asian population
demonstrates a higher prevalence than the Caucasian), if this
allele poses a genuine risk not only for those of Japanese
ancestry but also for other populations.
Although risk allele HLA-B*59:01 showed a signiﬁcant
association with CIAG, its clinical utility as a screening test
is limited with regard to predicting future CIAG in patients
being treated by CLZ for the ﬁrst time. Sensitivity and PPV
were low, indicating this allele is not suitable for a screening
test to target CIAG, especially for CIG. Speciﬁcity and NPV
were high, indicating that the test in general could be useful for
making a deﬁnitive diagnosis. However, the information pro-
vided by this risk allele is not necessary for the diagnosis of
CIAG, as deﬁnitive diagnosis is made by blood count. Taken
together, the predictive power estimated by our results
indicates this would not be useful for the clinical diagnosis
of CIAG (and/or CIA) when ﬁrst treating with CLZ.
However, our results based on explorative estimates may
provide evidence that CLZ rechallenging is a possible option
for patients when they respond only to CLZ. Using the
estimated proportion of non-CIAestimated/CIAestimated, we
observed the high sensitivity (to assess the non-CIAestimated
patients with the nonrisk allele) that can provide a key to
personalized medicine for CIG patients. However, in the real
world, we do not, of course, have a predictor to divide CIG
patients into non-CIA and CIA but only have allele information
of the risk with HLA-B*59:01. Therefore, the PPV is the most
informative value for CIG patients: if a patient has no risk allele,
indicating a lower risk for developing subsequent CIA (as with
approximately 80% of the CIG subjects [n 5 23/28]), they
would be a potent candidate for rechallenging with CLZ
treatment. Among these, it is of note that 60% of the CIG
subjects without HLA-B*59:01 have the potential to avoidpt for HLA-B*59:01) on non-CIA Among CIG Subjects
CIAestimated
a (%) Total (%) Sensitivity Speciﬁcity PPVb NPVb
35.3 82.1 .971 .318 .570 .923
16.5 17.9
51.8 100
33.0 82.1 .953 .318 .598 .863
15.4 17.8
48.4 100
ranulocytopenia; NPV, negative predictive value; PPV, positive
ated by ϕ.
and tolerant controls subjects, respectively, as prior probability.
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Psychiatryfuture CIA. Conversely, this means that 40% of the CIG
subjects without the risk allele may develop CIA. It is a
matter of clinical judgment whether or not this has a high
value, but given that there is no treatment strategy other than
CLZ to control the patient’s symptoms (30% to 40 % of
patients with CLZ treatment showed a very good response)
(26,27), and that mortality from CIG is not high under the
current monitoring system (2% to 4% even among CIA
subjects) (6), rechallenging will be one of the options to
control the severe symptoms for TRS. We stress, of course,
that frequent monitoring of the white blood cells and ANC is
essential regardless.
Although we replicated the association in the HLA-B gene
detected in the report by Goldstein et al. (19), several inclusion
criteria were not identical. For example, Goldstein et al. (19)
used a more stringent deﬁnition of CIG, the upper limit of the
ANC being less than 1000 cells/mm3. Whereas the deﬁnition of
the ANC we used was less than 1500 cells/mm3, which is in
accord with the Clozaril Patient Monitoring Service, it thus
could reﬂect the real-world clinical setting. To validate the
ﬁndings by Goldstein et al. (19), we conducted an explorative
analysis using the stringent ANC cutoff level (less than 1000
cells/mm3); we could replicate the signiﬁcant association
between HLA-B*59:01 and the CIAG subjects (CIA 1 stringent
CIG) with the ANC less than 1000 cells/mm3 (Supplemental
Table S4). Also, the effect size showed similar magnitude
between CIA (OR: 15.8/9.3 for comparison with healthy
control subjects/tolerant control subjects, respectively) and
the stringent CIG (OR: 13.5/7.9 for comparison with
healthy control subjects/tolerant control subjects, respectively;
further analysis by stratifying the subjects based on ANC
ranges is described in the Supplement text and Supplemental
Table S4), supporting HLA-B*59:01 as a genuine risk factor
for CIA.
Our study has several limitations. First, the deﬁnition of the
tolerant control was not perfect: epidemiological surveys
suggested that CIAG was observed at 80% in the ﬁrst 18
weeks and 90% by 1 year (8,10). Therefore, we would have to
monitor our subjects again to validate them as genuine
tolerant subjects; theoretically, however, approximately three
subjects out of 380 subjects (380 3 .04 3 .2 E 3) would
be the misclassiﬁed subjects under the assumptions of
the prevalence of CIAG as 4% and of the 20% (in a
worst-case scenario) of the subjects undetected at the earlier
stage, expecting low possibility to have a large impact on our
results. Lastly, our sample size was limited; therefore, further
replication with greater power is essential for clinical
application.
In summary, we identiﬁed the HLA risk for CIAG in the
Japanese population. The effect size is relatively large, but due
to the modest predictive power and population frequency of
the allele, it is difﬁcult to use this result as a predictive factor
for patients exposed to CLZ for the ﬁrst time. However, our
results indicate that rechallenging is a possible option for CIG
patients who have no risk allele when they respond only to
CLZ. Future identiﬁcation of risk factors other than HLA-
B*59:01 could provide a more accurate indicator to predict
CIAG, including environment factors, such as lower ANC in
the stable condition, drug interaction, or gene-environment
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